Navigation Links
Reportlinker Adds Shire plc: PharmaVitae Profile
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Shire plc: PharmaVitae Profile

http://www.reportlinker.com/p0177526/Shire-plc-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

  • Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector
  • Assess Shire's strategy for sustaining its market-leading ADHD portfolio beyond the genericization of blockbuster Adderall XR
  • Analyze the impact of recent acquisitions (TKT, New River Pharmaceuticals, Jerini) on Shire's financial and sales performance over 2008-14

  • ABOUT DATAMONITOR HEALTHCARE 2

    About the PharmaVitae team 2

    Chapter 1 About this profile 3

    PharmaVitae Explorer database 3

    Chapter structure 3

    Executive summary 3

    Quarterly news update 3

    Company introduction 4

    Company sales 4

    Company financials 4

    Key products and competitors 4

    Data sourcing 4

    Sales data 4

    Analyst consensus 4

    Chapter 2 Executive summary 5

    Key findings 5

    Prescription pharmaceutical sales and growth rate performance, 2002-14 6

    Financial performance, 2002-14 7

    Shire plc: PharmaVitae forecasts at a glance 8

    Strategic insight 9

    Shire's ADHD franchise growth 9

    Corporate restructuring: growth via M&A 10

    SWOT analysis 12

    Strengths 12

    Weaknesses 13

    Opportunities 14

    Threats 15

    Table of Contents 15

    Table of figures 17

    Chapter 3 Quarterly news update 18

    Product developments 18

    Deals and alliances 19

    Product deals 19

    Technology deals 20

    M&A activity 21

    Company announcements 21

    Future product milestones 22

    Chapter 4 Company introduction 23

    Key findings 23

    Background 24

    Key corporate developments 24

    M&A history 25

    Acquisition of Imperial Pharmaceutical Services 25

    Acquisition of Pharmavene 26

    Acquisition of Richwood 26

    Merger with Roberts Pharmaceutical Corporation 26

    Acquisition of Fuisz Technologies' EU subsidiaries 26

    Acquisition of BioChem Pharma 26

    Acquisition of Atlantic Pharmaceutical 26

    Divestment of OTC products 26

    Divestment of vaccines business 27

    Acquisition of Transkaryotic Therapies 27

    Acquisition of New River Pharmaceuticals 27

    Divestment of non-core products 27

    Acquisition of Jerini 27

    Current corporate structure 28

    Specialty Pharmaceuticals 28

    Human Genetic Therapies 28

    Chapter 5 Company sales 29

    Key findings 29

    Prescription pharmaceutical sales and growth rate analysis, 2002-14 30

    Product analysis 32

    Product analysis, 2002-08 33

    Product analysis, 2008-14 36

    Therapy area analysis 39

    Geographic analysis 41

    Launch/core/expiry analysis 44

    Explanation of launch/core/expiry analysis 44

    Launch analysis, 2008-14 45

    Core analysis, 2008-14 47

    Expiry analysis, 2008-14 48

    Launch/core/expiry configuration, 2008-14 49

    Molecule type analysis 50

    Externalization analysis 53

    Chapter 6 Company financials 55

    Key findings 55

    Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 56

    Operating costs and profit analysis 57

    Operating costs and profit analysis, 2002-08 58

    Operating cost ratio and profit margin analysis, 2002-08 59

    Operating cost ratio and profit margin analysis, 2008-14 60

    Operating costs and profit analysis, 2008-14 61

    Chapter 7 Key products and competitors 62

    Key findings 62

    Overview 63

    Central nervous system 64

    Vyvanse 64

    Overview 64

    Sales forecast 65

    Vyvanse-sustains Shire's ADHD focus beyond Adderall XR 65

    Vyvanse tackles Adult ADHD market 66

    Shire to gain growth in immature EU ADHD market with Vyvanse 66

    Actavis' challenge to Vyvanse's US exclusivity represents a longer-term threat to sales 66

    Intuniv 67

    Overview 67

    Sales forecast 68

    Intuniv is Shire's newest ADHD offering 68

    As a non-stimulant, Intuniv competes against Strattera 68

    Datamonitor maintains the view that positioning as a second-line treatment option will limit uptake of Intuniv 69

    More restrictive scheduling for Vyvanse raises forecasts for Intuniv 69

    Daytrana 70

    Overview 70

    Sales forecast 71

    Daytrana is the first transdermal patch formulation of methylphenidate 71

    Withdrawal of Daytrana European Marketing Authorization Application (MAA) in March 2009 71

    Voluntary market recall of a limited portion of Daytrana patches unlikely to threaten long-term sales 72

    Endocrine, metabolic and genetic disorders 73

    Elaprase 73

    Overview 73

    Sales forecast 74

    Enzyme replacement therapy Elaprase was gained in TKT acquisition 74

    Cost is also key to Elaprase's success 74

    Patent protection extended in 2008 74

    Replagal 75

    Overview 75

    Sales forecast 76

    Replagal gains access to US market following Fabrazyme manufacturing concerns 76

    Replagal becomes Shire's first HGT offering 76

    Fabrazyme shortage grants US opportunity for Replagal 77

    Velaglucerase alfa 78

    Overview 78

    Sales forecast 79

    Limited availability of velaglucerase alfa until 2010 79

    Velaglucerase alfa to compete with Genzyme's Cerezyme 79

    Shire's clinical data was solid, but is there an unmet need? 80

    Gastroenterology 81

    Lialda / Mezavant 81

    Overview 81

    Sales forecast 82

    Shire to roll-out Lialda across the rest of the EU 82

    Lialda and Pentasa can co-exist in the US market 82

    Takeda/TAP co-promotion from 2008 83

    Pricing may prove a resistor to Lialda's sales growth 83

    Pentasa 84

    Overview 84

    Sales forecast 85

    Bullets Shire license Pentasa from Ferring for the US market 85

    US patent expiry in 2008 unlikely to impact sales 85

    Pentasa and Lialda co-exist without signs of cannibalization 86

    Genitourinary 87

    Fosrenol 87

    Overview 87

    Sales forecast 88

    Fosrenol licensed from AnorMED 88

    Abbott terminates co-promotion agreement for the US market 88

    US market flattening out, EU and RoW to show strong growth 88

    Generic threat lingers on... 89

    Chapter 8 Appendix 90

    R&D pipeline 90

    References 91

    Abbreviations 91

    Exchange rates 92

    About Datamonitor 93

    About Datamonitor Healthcare 93

    Datamonitor consulting 93

    Disclaimer 94

    Disclaimer 95

    List of Tables Table 1: Shire - PharmaVitae forecasts at a glance 8

    Table 2: Shire key product developments, 2009 18

    Table 3: Shire product deals and alliances, 2009 19

    Table 4: Shire technology deals and alliances, 2009 20

    Table 5: Shire M&A activity, 2009 21

    Table 6: Shire company announcements, 2009 21

    Table 7: Shire future product milestones, 2009-11 22

    Table 8: Shire product portfolio overview ($m), 2002-08 33

    Table 9: Shire product portfolio overview ($m), 2008-14 36

    Table 10: Shire prescription pharmaceutical sales by therapy area ($m), 2008-14 40

    Table 11: Shire prescription pharmaceutical sales by geographic region ($m), 2008-14 42

    Table 12: Shire launch portfolio overview ($m), 2008-14 45

    Table 13: Shire core portfolio overview ($m), 2008-14 47

    Table 14: Shire expiry portfolio overview ($m), 2008-14 48

    Table 15: Shire prescription pharmaceutical sales by molecule type ($m), 2008-14 51

    Table 16: Shire prescription pharmaceutical sales by source ($m), 2008-14 54

    Table 17: Total Shire sales by business unit ($m), 2002-08 56

    Table 18: Shire operating revenue/cost analysis ($m), 2002-08 58

    Table 19: Shire operating cost ratio analysis (% of total revenues), 2002-08 59

    Table 20: Shire operating cost ratio analysis (% of total revenues), 2008-14 60

    Table 21: Shire operating revenue/cost analysis ($m), 2008-14 61

    Table 22: Key products overview 63

    Table 23: Vyvanse: overview 64

    Table 24: Vyvanse: sales forecast ($m), 2008-14 65

    Table 25: Intuniv: overview 67

    Table 26: Intuniv: sales forecast ($m), 2008-14 68

    Table 27: Daytrana: overview 70

    Table 28: Daytrana: sales forecast ($m), 2008-14 71

    Table 29: Elaprase: overview 73

    Table 30: Elaprase: sales forecast ($m), 2008-14 74

    Table 31: Replagal: overview 75

    Table 32: Replagal: sales forecast ($m), 2008-14 76

    Table 33: Velaglucerase alfa: overview 78

    Table 34: Velaglucerase alfa: sales forecast ($m), 2008-14 79

    Table 35: Lialda / Mezavant: overview 81

    Table 36: Lialda / Mezavant: sales forecast ($m), 2008-14 82

    Table 37: Pentasa: overview 84

    Table 38: Pentasa: sales forecast ($m), 2008-14 85

    Table 39: Fosrenol: overview 87

    Table 40: Fosrenol: sales forecast ($m), 2008-14 88

    Table 41: Shire's R&D pipeline (Phase I-registration) 90

    Table 42: Exchange rates, 2009 92

    List of Figures Figure 1: The PharmaVitae Explorer 3

    Figure 2: Shire prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

    Figure 3: Shire's financial performance ($m), 2002-14 7

    Figure 4: Shire ADHD franchise - switching strategy, 2001-14 9

    Figure 5: Shire revenue by source of product, $m, 2002-14 10

    Figure 6: Shire SWOT analysis 12

    Figure 7: Shire M&A/divestment history 25

    Figure 8: Current corporate structure 28

    Figure 9: Shire prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 30

    Figure 10: Key product sales ($m), 2002-14 32

    Figure 11: Shire key sales growth drivers and resistors ($m), 2002-08 34

    Figure 12: Shire key sales growth drivers and resistors ($m), 2008-14 37

    Figure 13: Shire prescription pharmaceutical sales by therapy area ($m), 2002-14 39

    Figure 14: Shire prescription pharmaceutical sales by geographic region ($m), 2002-14 41

    Figure 15: Shire launch/core/expiry configuration ($m), 2008-14 49

    Figure 16: Shire prescription pharmaceutical sales by molecule type ($m), 2002-14 50

    Figure 17: Shire prescription pharmaceutical sales by source ($m), 2002-14 53

    Figure 18: Shire operating revenue/cost analysis ($m), 2002-14 57

    To order this report:Pharmaceutical Industry: Shire plc: PharmaVitae Profile

    Pharmaceutical Business News

    More  Market Research Report

    Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
    '/>"/>

    SOURCE Reportlinker
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
    2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
    3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
    4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
    5. Reportlinker Adds Nanomedicine Report
    6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
    7. Reportlinker Adds Nanoporous Materials Report
    8. Reportlinker Adds Membrane Bioreactors Report
    9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
    10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
    11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
    (Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
    (Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
    (Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
    Breaking Biology Technology:
    (Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
    (Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
    (Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
    Breaking Biology News(10 mins):